Login to Your Account

Three-Target Merck Serono Collaboration

F-Star Scores $691M Antibody Deal for Inflammatory Disease

By Nuala Moran

Thursday, September 8, 2011
LONDON – Antibody engineering specialist F-Star GmbH landed a second partner for its novel antibody formats, signing up Merck Serono SA in an inflammatory disease deal with a headline value of €492 million (US$691.1 million).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription